<DOC>
	<DOCNO>NCT00731133</DOCNO>
	<brief_summary>This 8 week , open-label pilot clinical trial examine safety tolerability disulfiram 250 mg/day fifteen methamphetamine dependent individual . After undergo screening procedure ( approximately one week ) , eligible subject enter study proper attend clinic every weekday week 1 trial order receive disulfiram observation complete assessment . Then subject receive weekly blister pack medication attend clinic thrice weekly week 2-6 . During week 7-8 , subject long take disulfiram , follow two week , refer treatment elsewhere , desire . Urine sample obtain disulfiram side-effects checklist complete thrice-weekly . Self-reported drug use , crave mood rating complete weekly . All subject undergo cognitive behavioral therapy . Adjunctive contingency management procedure utilized enhance retention . The primary outcome interest include retention , side-effects , drug use . Our hypothesis disulfiram well tolerated population .</brief_summary>
	<brief_title>Open-Label Disulfiram Methamphetamine Dependence</brief_title>
	<detailed_description>This 8 week , open-label pilot clinical trial examine safety tolerability disulfiram 250 mg/day fifteen methamphetamine dependent individual . After undergo screening procedure ( approximately one week ) , eligible subject enter study proper attend clinic every weekday week 1 trial order receive disulfiram observation complete assessment . Then subject receive weekly blister pack medication attend clinic thrice weekly week 2-6 . During week 7-8 , subject long take disulfiram , follow two week , refer treatment elsewhere , desire . Urine sample obtain disulfiram side-effects checklist complete thrice-weekly . Self-reported drug use , crave mood rating complete weekly . All subject undergo cognitive behavioral therapy . Adjunctive contingency management procedure utilized enhance retention . The primary outcome interest include retention , side-effects , drug use . Results study provide initial safety drug use data grant application propose examine clinical efficacy disulfiram similar agent treat methamphetamine dependence placebo-controlled , double-blind condition .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Disulfiram</mesh_term>
	<criteria>1865 year old currently enrol treatment program subject must history methamphetamine use recent use confirm positive urine toxicology screen amphetamine month prior study entry subject must meet DSMIV criterion amphetamine dependence assess substance abuse section Structured Clinical Interview DSMIV ( SCID ) woman childbearing age must negative pregnancy test enroll study , agree monthly pregnancy testing , agree use appropriate form birth control duration study . current diagnosis alcohol physical dependence significant medical condition abnormal liver function ( e.g. , laboratory finding ALT AST great three time normal ) , active hepatitis , uncontrolled hypertension , current cardiac condition high risk cardiovascular disease ( see section c.1 ) , seizure disorder , another significant underlying medical condition would contraindicate disulfiram treatment meeting DSMIV psychiatric classification schizophrenia , bipolar disorder , psychotic disorder exhibit current suicidality homicidality pregnancy breastfeed current use prescribe psychotropic medication ( e.g. , antidepressant , anxiolytic , antipsychotic , anticonvulsant , etc . ) discontinue current use medication anticoagulant , isoniazid , metronidazole , clotrimazole , paraldehyde</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>disulfiram</keyword>
	<keyword>methamphetamine dependence</keyword>
	<keyword>open label</keyword>
</DOC>